Last updated: March 30, 2023
Sponsor: Rohto Pharmaceutical Co., Ltd.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Hyponatremia
Scar Tissue
Hepatic Fibrosis
Treatment
N/AClinical Study ID
NCT03472742
ADR-001-02
Ages > 20 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Liver cirrhosis patients enrolled in ADR-001-01 study and completed the lastobservation of the study
- Voluntary signed informed consent
Exclusion
Exclusion Criteria:
- Patients evaluated by investigators as inappropriate
Study Design
Total Participants: 21
Study Start date:
March 07, 2018
Estimated Completion Date:
February 29, 2024
Connect with a study center
Niigata University Medical & Dental Hospital
Niigata, 951-8510
JapanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.